Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q
FLORHAM PARK, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company, announced […]
Prairie Operating Co. Announces Board Resignation
HOUSTON, Texas, Nov. 01, 2024 (GLOBE NEWSWIRE) — Prairie Operating Co. (Nasdaq: PROP) (the “Company” or “Prairie”) today announces that […]
HII Hosts United Kingdom Defense Leaders at Newport News Shipbuilding
NEWPORT NEWS, Va., Nov. 01, 2024 (GLOBE NEWSWIRE) — HII (NYSE: HII) hosted United Kingdom defense leaders at the company’s […]
Taseko to Release Third Quarter 2024 Results
VANCOUVER, British Columbia, Nov. 01, 2024 (GLOBE NEWSWIRE) — Taseko Mines Limited (TSX: TKO; NYSE American: TGB; LSE: TKO) (the […]
TSX News -
Conference Call – 4th Quarter 2024 Results
VANCOUVER, British Columbia, Nov. 01, 2024 (GLOBE NEWSWIRE) — Rogers Sugar Inc. (RSI) will be holding a conference call to […]
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
IMPACT-TD Registry, the largest study evaluating holistic effects of tardive dyskinesia (TD), highlights that there is a high burden of […]
Natural Gas Services Group, Inc. Announces the Appointment of Jean Holley to its Board of Directors
Midland, Texas, Nov. 01, 2024 (GLOBE NEWSWIRE) — Natural Gas Services Group, Inc. (“NGS” or the “Company”) (NYSE: NGS), a […]
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-‘749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone)
Teva’s presentation of findings from six schizophrenia studies at Psych Congress 2024 highlights its commitment to finding new innovations in […]
